Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket
- 14 August 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (17) , 9828-9837
Abstract
Clinical use of phosphodiesterase-5 (PDE5) inhibitors is limited by several side effects due to weak isoform selectivity. Herein, a unique allosteric pocket of PDE5 is identified by molecular modelling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO). The crystal structure of PDE5 with bound EVO derivative (S)-7e revealed that binding of (S)-7e to the novel allosteric pocket induced dramatic conformation changes of the H-loop with a maximum 24 Å movement of their Cα atoms. This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. These derivatives showed >570 fold selectivity over PDE6C and PDE11A and achieved potent efficacy for the effective treatment of pulmonary hypertension in vivo.Keywords
Funding Information
- National Natural Science Foundation of China (21877134, 81525020, 81703341, 81725020)
- National Institute of General Medical Sciences (GM59791)
- Guangdong Province
- Science Foundation of Guangzhou City (201904020023)
This publication has 36 references indexed in Scilit:
- Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyondNature Reviews Drug Discovery, 2019
- Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by PhosphodiesterasesAnnual Review of Pharmacology and Toxicology, 2017
- Cyclic AMP (cAMP) signaling in melanocytes and melanomaArchives of Biochemistry and Biophysics, 2014
- Advances in targeting cyclic nucleotide phosphodiesterasesNature Reviews Drug Discovery, 2014
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6Medicinal Research Reviews, 2005
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Structural and Functional Features in Human PDE5A1 Regulatory Domain That Provide for Allosteric cGMP Binding, Dimerization, and RegulationJournal of Biological Chemistry, 2005
- PDE5 is converted to an activated state upon cGMP binding to the GAF A domainThe EMBO Journal, 2003
- Phosphodiesterase 5 inhibitors: current status and potential applicationsNature Reviews Drug Discovery, 2002